Cargando…
Prevalence of growth hormone (GH) deficiency in previously GH‐treated young adults with Prader‐Willi syndrome
OBJECTIVE: Some features of subjects with Prader‐Willi syndrome (PWS) resemble those seen in growth hormone deficiency (GHD). Children with PWS are treated with growth hormone (GH), which has substantially changed their phenotype. Currently, young adults with PWS must discontinue GH after attainment...
Autores principales: | Donze, Stephany H., Damen, Layla, van Alfen‐van der Velden, Janiëlle A. E. M., Bocca, Gianni, Finken, Martijn J. J., Hoorweg‐Nijman, Gera J. G., Jira, Petr E., van Leeuwen, Mariëtte, Hokken‐Koelega, Anita C. S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6850120/ https://www.ncbi.nlm.nih.gov/pubmed/30973645 http://dx.doi.org/10.1111/cen.13988 |
Ejemplares similares
-
Evidence for Accelerated Biological Aging in Young Adults with Prader–Willi Syndrome
por: Donze, Stephany H, et al.
Publicado: (2019) -
Effect of cessation of GH treatment on cognition during transition phase in Prader-Willi syndrome: results of a 2-year crossover GH trial
por: Kuppens, R. J., et al.
Publicado: (2016) -
Three years of growth hormone treatment in young adults with Prader-Willi syndrome: sustained positive effects on body composition
por: Damen, Layla, et al.
Publicado: (2020) -
Prenatal and Neonatal Characteristics of Children with Prader-Willi Syndrome
por: Grootjen, Lionne N., et al.
Publicado: (2022) -
Oxytocin in young children with Prader‐Willi syndrome: Results of a randomized, double‐blind, placebo‐controlled, crossover trial investigating 3 months of oxytocin
por: Damen, Layla, et al.
Publicado: (2020)